Skip to main content

Table 1 Pairwise meta-analysis of antibiotics of clinical cure in cSSSI and HAP/VAP in mITT population

From: Network meta-analysis and pharmacoeconomic evaluation of antibiotics for the treatment of patients infected with complicated skin and soft structure infection and hospital-acquired or ventilator-associated penumonia

Treatment comparisons Number of studies Pairwise meta-analysis Odds ratio (95% CI) P value Heterogeneity I2, % (variation in OR attributable to heterogeneity)
cSSSI
 Vancomycin vs Oritavancin 2 0.96 (0.59, 1.56) 0.867 0.0
 Vancomycin vs Daptomycin 4 1.04 (0.79, 1.36) 0.756 0.0
 Vancomycin vs Telavancin 4 0.86 (0.61, 1.24) 0.430 0.0
 Vancomycin vs Tigecycline 3 1.15 (0.79, 1.66) 0.451 0.0
 Vancomycin vs Ceftaroline 4 0.94 (0.71, 1.26) 0.695 0.0
 Vancomycin vs Dalbavancin 2 1.00 (0.77, 1.31) 0.973 0.0
 Vancomycin vs Ceftobiprole 2 0.78 (0.33, 1.82) 0.565 0.0
 Linezolid vs Vancomycin 5 1.23 (1.09, 1.50) 0.006 0.0
 Linezolid vs Dalbavancin 1 0.84 (0.39, 1.82) 0.673
 Linezolid vs SXT/rifampicin 1 0.70 (0.16, 2.95) 0.627
 Linezolid vs Omadacycline 1 0.36 (0.03, 4.18) 0.417
 Linezolid vs Fusidic Acid 1 2.71 (0.83, 8.89) 0.099
 Linezolid vs JNJ-Q2 1 0.95 (0.45, 1.94) 0.682
 Linezolid vs Tedizolid 2 1.09 (0.58, 2.02) 0.780 0.0
 Linezolid vs Teicoplanin 1 0.52 (0.15, 1.79) 0.234
HAP/VAP
 Vancomycin vs Telavancin 2 1.02 (0.85, 1.23) 0.822 0.0
 Vancomycin vs Vancomycin/rifampicin 1 1.49 (0.72, 3.06) 0.278
 Vancomycin vs Quinupristin/dalfopristin 1 1.03 (0.71, 1.51) 0.858
 Linezolid vs Vancomycin 8 1.11 (0.91, 1.34) 0.301 0.0
 Linezolid vs Ceftobiprole 1 0.53 (0.17, 1.57) 0.251
 Linezolid vs Teicoplanin 1 0.38 (0.07, 2.16) 0.279
 Linezolid vs SXT/rifampicin 1 1.77 (0.25, 12.45) 0.562
  1. cSSSI complicated skin and soft structure infection, HAP/VAP hospital-acquired or ventilator-associated pneumonia, mITT modified intention-to-treat population, JNJ-Q2 a novel fluoroquinolone, SXT trimethoprim/sulfamethoxazole